Prognostic Biomarkers in Isocitrate Dehydrogenase Wild-Type Glioblastoma: A Focus on B7-H3

Basit Öğe Kaydı
dc.contributor.authorYuceer, Ramazan Oguz
dc.contributor.authorKaya, Seyhmus
dc.contributor.authorBalci, Sema Nur
dc.contributor.authorEgilmez, Hatice Reyhan
dc.contributor.authorYilmaz, Mukaddes
dc.contributor.authorErdis, Eda
dc.date.accessioned2025-05-04T16:45:44Z
dc.date.available2025-05-04T16:45:44Z
dc.date.issued2025
dc.departmentSivas Cumhuriyet Üniversitesi
dc.description.abstractBackground: Isocitrate dehydrogenase (IDH) wild-type (wt) glioblastoma is an aggressive malignancy associated with poor clinical outcomes, marked by high heterogeneity and resistance to treatment. This study aims to investigate the prognostic significance of B7-H3 expression in IDH wt glioblastoma and its potential association with clinical outcomes, including overall survival (OS) and progression-free survival (PFS). Additionally, the relationship between B7-H3 and PD-L1 expression was explored. Methods: A retrospective cohort of 86 IDH wt glioblastoma patients, all of whom underwent surgery, radiotherapy, and temozolomide treatment, was analyzed. B7-H3 expression was quantified using an immunoreactivity score (IRS), classifying samples as low (IRS <= 4) or high (IRS > 4). PD-L1 expression was evaluated based on tumor and immune cell staining, with >5% positivity indicating significant expression. Results: High B7-H3 expression was significantly associated with poorer OS and PFS. Co-expression of B7-H3 and PD-L1 was prevalent, particularly among younger male patients with unifocal tumors; however, PD-L1 expression did not show a significant correlation with clinical outcomes. Conclusions: B7-H3 appears to be a promising prognostic biomarker in IDH wt glioblastoma and may serve as a target for developing combination therapies, integrating B7-H3-targeting treatments with immune checkpoint inhibitors. Further prospective studies are necessary to validate these findings and to explore potential therapeutic strategies.
dc.identifier.doi10.3390/brainsci15020212
dc.identifier.issn2076-3425
dc.identifier.issue2
dc.identifier.pmid40002543
dc.identifier.scopus2-s2.0-85218676636
dc.identifier.scopusqualityQ3
dc.identifier.urihttps://doi.org/10.3390/brainsci15020212
dc.identifier.urihttps://hdl.handle.net/20.500.12418/35204
dc.identifier.volume15
dc.identifier.wosWOS:001432257600001
dc.identifier.wosqualityQ3
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherMDPI
dc.relation.ispartofBrain Sciences
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/openAccess
dc.snmzKA_WOS_20250504
dc.subjectglioblastoma
dc.subjectB7-H3
dc.subjectPD-L1
dc.subjectimmune checkpoint
dc.subjectsurvival
dc.subjectIDH wild type
dc.subjectbrain tumor
dc.subjectbiomarker
dc.subjectCD276
dc.subjectadult-type diffuse glioma
dc.titlePrognostic Biomarkers in Isocitrate Dehydrogenase Wild-Type Glioblastoma: A Focus on B7-H3
dc.typeArticle

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksyonu
Scopus İndeksli Yayınlar Koleksiyonu